Epidemiologic Research of Rare Cancers: Trends, Resources, and Challenges.
Biomedical Research
/ statistics & numerical data
Epidemiologic Studies
Humans
Incidence
National Cancer Institute (U.S.)
/ statistics & numerical data
Neoplasms
/ epidemiology
Prevalence
Professional Practice Gaps
/ statistics & numerical data
Rare Diseases
/ epidemiology
SEER Program
/ statistics & numerical data
Survival Rate
United States
/ epidemiology
Journal
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
ISSN: 1538-7755
Titre abrégé: Cancer Epidemiol Biomarkers Prev
Pays: United States
ID NLM: 9200608
Informations de publication
Date de publication:
07 2021
07 2021
Historique:
received:
19
12
2020
revised:
15
02
2021
accepted:
10
03
2021
pubmed:
3
4
2021
medline:
22
2
2022
entrez:
2
4
2021
Statut:
ppublish
Résumé
The goals of this project were to assess the status of NCI's rare cancer-focused population science research managed by the Division of Cancer Control and Population Sciences (DCCPS), to develop a framework for evaluation of rare cancer research activities, and to review available resources to study rare cancers. Cancer types with an overall age-adjusted incidence rate of less than 20 cases per 100,000 individuals were identified using NCI Surveillance, Epidemiology and End Results (SEER) Program data. SEER data were utilized to develop a framework based on statistical commonalities. A portfolio analysis of DCCPS-supported active grants and a review of three genomic databases were conducted. For the 45 rare cancer types included in the analysis, 123 active DCCPS-supported rare cancer-focused grants were identified, of which the highest percentage (18.7%) focused on ovarian cancer. The developed framework revealed five clusters of rare cancer types. The cluster with the highest number of grants ( This article provides an overview of the rare cancer-focused population sciences research landscape as well as information on gaps and opportunities. The findings of this article can be used to develop efficient and comprehensive strategies to accelerate rare cancer research.
Sections du résumé
BACKGROUND
The goals of this project were to assess the status of NCI's rare cancer-focused population science research managed by the Division of Cancer Control and Population Sciences (DCCPS), to develop a framework for evaluation of rare cancer research activities, and to review available resources to study rare cancers.
METHODS
Cancer types with an overall age-adjusted incidence rate of less than 20 cases per 100,000 individuals were identified using NCI Surveillance, Epidemiology and End Results (SEER) Program data. SEER data were utilized to develop a framework based on statistical commonalities. A portfolio analysis of DCCPS-supported active grants and a review of three genomic databases were conducted.
RESULTS
For the 45 rare cancer types included in the analysis, 123 active DCCPS-supported rare cancer-focused grants were identified, of which the highest percentage (18.7%) focused on ovarian cancer. The developed framework revealed five clusters of rare cancer types. The cluster with the highest number of grants (
CONCLUSIONS
This article provides an overview of the rare cancer-focused population sciences research landscape as well as information on gaps and opportunities.
IMPACT
The findings of this article can be used to develop efficient and comprehensive strategies to accelerate rare cancer research.
Identifiants
pubmed: 33795213
pii: 1055-9965.EPI-20-1796
doi: 10.1158/1055-9965.EPI-20-1796
pmc: PMC8254778
mid: NIHMS1685500
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1305-1311Subventions
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
©2021 American Association for Cancer Research.
Références
Public Health Rep. 2010 Jan-Feb;125(1):28-43
pubmed: 20402194
CA Cancer J Clin. 2017 Jul 8;67(4):261-272
pubmed: 28542893